A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-77242113 in Healthy Japanese Participants and a Single Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-77242113 in Healthy Chinese Participants
Latest Information Update: 24 Nov 2022
At a glance
- Drugs PN-235 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 22 Nov 2022 Status changed from recruiting to completed.
- 29 Aug 2022 Number of arms changed from 3 to 4. Experimental cohort 4: JNJ-77242113 or Placebo (SD) added to study. Planned number of patients also increased.
- 29 Aug 2022 Planned number of patients changed from 27 to 36.